Dear Colleagues,

An inflammatory tumor microenvironment is associated with all stages of cancer development, including initiation, promotion and progression. The prognostic implications of systemic inflammation in the tumor microenvironment are increasingly recognized in cancer patients. Despite its potential for revolutionizing cancer treatment, cancer immunotherapy also presents new challenges due to its ability to induce tumor resistance and to alter the patient's innate and adaptive immune responses. Cancer cells actively interact with the immune system, and cancer-specific immunotherapies also engage with the immune system and tumor in these dynamic interactions. Understanding such interactions should help to develop novel combination therapies and sequencing approaches. This Special Issue seeks articles, reviews and perspectives on cancer immunotherapy in the clinical and translational settings. These can include in vitro and in vivo studies on immunotherapeutic approaches, tumor-immune cell interactions, immunotherapy biomarkers, and acquired immunity resistance. The cellular microenvironment can also be affected by dietary habits, environmental factors, imbalances in the intestinal flora, and abnormal tumor growth induced by innate genes. Certain metabolic pathways and metabolites are specific to particular types of tumor cells. This Special Issue also welcomes papers on mechanisms involved in the growth and metabolism of tumor cells, as well as studies that investigate how tumor therapy regulates metabolism.

Dr. Chan-Yen Kuo
Guest Editor